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We presented a case of an 82-year-old manwho had classic Kaposi sarcoma. He took thalidomide 100 mg
twice daily for 23 days, and then he felt light-headedness and visited our emergency department. The
heartbeat changes from baseline 80 beats per minute before administration of thalidomide to 45 beats
per minute. About 25e50% of patients using thalidomide had mild bradycardia, and only 1e3% with
severe bradycardia needed the assistance of inotropic agent or device (transcutaneous cardiac pacing).
Emergency physicians should keep in mind current and concurrent medications in bradycardiac patients
who are presented to the emergency department. If patients need thalidomide treatment, avoiding
concomitant usage of beta-blocker and doing regular electrocardiogram monitoring are mandatory. In
this case, atropine helps to improve the dizziness resulting from thalidomide-related bradycardia.
Copyright  2010, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Classic Kaposi sarcoma (CKS) is a prevalent and indolent
neoplasm among Eastern European and Mediterranean origin. It is
a rare neoplasm that principally affects the skin of the lower
extremities in a multifocal fashion.1 Thalidomide (N-
phthalimidoglutarimide) was initially manufactured in West
Germany and marketed as an antiemetic and sedative until 1960s.
It functions as a potent immunosuppressive and antiangiogenic
agent by inhibiting the phagocytic ability of inﬂammatory cells
and the production of cytokines, such as tumor necrosis factor
a (TNF-a), by enhancing the degradation of its messenger RNA. It
has been shown to be effective in the treatment of inﬂammatory
diseases, conditions associated with human immunodeﬁciency
virus (HIV) infection, and in various cancers.2 Common side effects
include peripheral neuropathy, constipation, rash, and
neutropenia. Thrombotic events, bradycardia, tremor, and
hypothyroidism are less common side effects.3. However, high
incidence of bradyarrhythmias in these patients was observed in
several studies. We present a patient with non-HIV KS treated
with thalidomide in the following section.erest.
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An 82-year-old man had histories of old cerebrovascular acci-
dent, hypertension, chronic renal insufﬁciency, and benign prostate
hyperplasia. He complained of one dark patch on left sole for years,
one protruding mass for weeks, and three irregular dark bluish
patches (about 5  3 cm2) on left sole with one eroded protruding
round tumor (1 cm in diameter). KS was diagnosed by biopsy. He
started to take thalidomide, 200 mg twice daily. Concurrent
medications for constipation including sennoside two tablets per
day before sleep and magnesium oxide two tablets three times
a day were prescribed. Before thalidomide was administrated, the
heart rate was approximate 80 beats per minute. Thalidomide was
held 1 month later because of dizziness and constipation at
outpatient department. Thereafter, thalidomide was resumed 100
mg twice daily half month later because of symptoms (dizziness
and constipation) that subsided, and a new lesion over right sole
was seen. One month later, however, he presented with dizziness
again and went to our emergency room. On arrival, vital signs were
as follows: body temperature, 36.3C; pulse rate, 45 beats per
minute; respiratory rate, 18 times per minute; blood pressure, 145/
63 mmHg. Electrocardiogram showed sinus bradycardia (Fig. 1),
and laboratory studies disclosed the following values:
hemoglobin, 13.1 g/dL; white blood cell count, 7,400/mL; glucose,
176 mg/dL; glutamate oxaloacetate transaminase, 14 IU/L;
creatine kinase, 30 U/L; creatinine, 1.1 mg/dL; potassium, 4 mEq/
L; sodium, 135 mEq/L; creatine kinase-muscle and brain, 1 U/L;cy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. After administration of thalidomide 100 mg twice daily, electrocardiogram showed sinus bradycardia with pulse rate of 45 beats per minute, and he felt dizziness on arrival of
our emergency department.
C.-H. Tseng et al.198and troponin I, <0.1 ng/mL. Although the blood pressure is not low,
he felt dizzy from the heartbeat of 80e45 after treatment with
thalidomide. After atropine injection (1-mg, 0.5-mg, 0.5-mg
intravenous push, divided three times) and discontinuation of
thalidomide, the patient’s heart rate returned to approximate 50
beats per minute. He felt better and was discharged from
emergency room the next day.
3. Discussion
Themechanism in one observation supposed that the nucleus of
vagal nerve is rapidly and completely inhibited by exposure to TNF-
a. Because thalidomide inhibits TNF-a expression and activity, it
could lead to overactivity of the parasympathetic system, and bra-
dycardia was induced.4 Clinical trials and postmarketing
surveillances suggest that the incidence of thalidomide-related
mild bradycardia is 25e50% and severe bradycardia causing
syncope or hypotension is low, only 1e3% that pacemaker is
needed.3 Treatment with thalidomide should be initiated at
a dose of 100e200 mg/d and escalated weekly by 50e100 mg/
d until reaching the ﬁnal dose of 400e800 mg/d. The maximum
tolerated dose should be administered. Patients receiving daily
doses of 200 mg or less seem to tolerate the treatment well with
few side effects. However, almost all patients taking more than
400 mg/d have thalidomide-related toxicity. Thalidomide is
usually administered at bedtime to minimize somnolence and
fatigue.4,5 In our patient with thalidomide to an initial maximum
dose of 400 mg/d, the heart rate decreased markedly, resulting in
intermittent symptoms of light-headedness and dizziness. There-
fore, regular electrocardiogram monitoring is considered and anti-
hypertensive drugs such as beta-blockers should be avoided when
using thalidomide. In severe cases, temporary pacing is indicated.5
On the other hand, various treatments have been used to treat CKS.
Surgery, formerly recommended, is no longer indicated apart from
solitary lesion and tissue analysis. The tendency toward
multifocality makes radiation therapy or chemotherapy, or both,
the preferred mode of treatment. Radiation therapy is animportant treatment, used for many years in CKS. Lesions of KS
are highly radiosensitive. Intralesional injection of vinblastine
sulfate is the most commonly used treatment regimen because it
is fast, inexpensive, and shows high response rates in the
treatment of skin lesions in KS. Costa da Cunha et al.6 reported
experiences of recombinant interferon-alfa (5 million U three
times weekly for at least 6 months) in 16 patients with noneHIV-
related KS in the year of 1996. Limited relapse was noted in only
four patients after withdrawal of interferon. However, toxic effects
included transient fever, fatigue, weight loss, transient
neutropenia, and a depressive syndrome.6e8 Thalidomide-induced
bradycardia appears to be an important adverse effect, particularly
in patients with maximal dosage of 400 mg/d. Therefore, providers
should monitor these patients closely for signs and symptoms of
bradycardia during the administration of thalidomide. Bradycardia
was decreased by a reduction in dose or discontinuation of thalid-
omide, suggesting a reversible effect on sinus node function. In
severe case with hypotension and syncope, temporary pacing will
be considered an effective therapeutic as radiotherapy or chemo-
therapy could be used.References
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